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Abstract
The X-linked myotubular myopathy (XLMTM) also called X-linked centronu-
clear myopathy is a rare congenital myopathy due to mutations in the MTM1
gene encoding myotubularin. The disease gives rise to a severe muscle weakness
in males at birth. The main muscle morphological characteristics (significant
number of small muscle fibers with centralized nuclei and type 1 fiber predomi-
nance) are usually documented, but the sequence of formation and mainte-
nance of this particular morphological pattern has not been extensively
characterized in humans. In this study, we perform a reevaluation of morpho-
logical changes in skeletal muscle biopsies in severe XLMTM. We correlate the
pathologic features observed in the muscle biopsies of 15 newborns with
MTM1-mutations according to the “adjusted-age” at the time of muscle biopsy,
focusing on sequential analysis in the early period of the life (from 34 weeks of
gestation to 3 months of age). We found a similar morphological pattern
throughout the period analyzed; the proportion of myofibers with central nuclei
was high in all muscle biopsies, independently of the muscle type, the age of
the newborns at time of biopsy and the specific MTM1 mutation. We did not
observe a period free of morphological abnormalities in human skeletal muscle
as observed in myotubularin-deficient mouse models. In addition, this study
demonstrated some features of delayed maturation of the muscle fibers without
any increase in the number of satellite cells, associated with a marked disorgani-
zation of the muscle T-tubules and cytoskeletal network in the skeletal muscle
fibers.
Introduction
The X-linked neonatal form of myotubular myopathy
(XLMTM, OMIM 310400) is the most severe form of
centronuclear myopathy. The disease is caused by muta-
tions in the MTM1 gene encoding myotubularin (MTM1)
(Laporte et al. 1996). The severe neonatal form is charac-
terized by hypotonia, muscle weakness, hypotrophy, and
respiratory failure requiring assisted ventilation immedi-
ately after birth. The early survival can be compromised
in male infants. Nonetheless some patients can, some-
times with severe disabilities, survive into childhood,
adolescence, and even adulthood (Biancalana et al. 2003;
Bertini et al. 2004; Hoffjan et al. 2006; Tosch et al. 2010).
Survival rate may differ in various countries (McEntagart
et al. 2002). The incidence of molecularly confirmed
XLMTM is estimated at 1/100,000 male births per year
(Biancalana et al. 2012).
Muscle biopsies are characterized by a large number of
small muscle fibers with central nuclei resembling myotu-
bes and a type 1 fiber predominance (reviews in Fardeau
1982; North 2004; Romero 2010; Romero and Bitoun
2011). Since these morphological findings resemble an
early stage of fetal muscle development, myotubular
476 ª 2013 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. This is an open access article under the terms of
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myopathy has been proposed to result from an arrest in
myogenesis (Sarnat 1990). In contrast to XLMTM new-
born patients, the Mtmt1-null mice show no symptoms at
birth but develop a progressive muscle disorder starting
in the hind limbs at 3–4 weeks of age, leading to severe
generalized amyotrophy and early death by about 7–
12 weeks of age (Buj-Bello et al. 2002). Several weeks
after birth the Mtm1-null mice begin to show the same
histological features observed in XLMTM newborn
patients, with muscle fiber atrophy, an increased propor-
tion of type 1 fibers and centralization of nuclei. As mus-
cle differentiation and maturation in Mtm1-null mice
appears normal during the early stages of life, it has been
proposed that defects in maintenance of muscle cell archi-
tecture might be responsible for the centralization of
nuclei and mislocalization of organelles. Defects in triad
structure and in calcium homeostasis may play an impor-
tant physiopathological role in myotubular myopathy (Al-
Qusairi et al. 2009; Dowling et al. 2009; Al-Qusairi and
Laporte 2011; Toussaint et al. 2011).
The aim of our present study was to characterize the
exact sequence of pathological events which occur in new-
born infants with myotubular myopathy. Therefore, (a)
We have reevaluated the morphological features of skele-
tal muscle biopsies according to the “adjusted-age” or age
of XLMTM newborns at the time of the muscle biopsy;
(b) We have analyzed the findings in muscle biopsies
taken from two different territories (vastus lateralis and
deltoid); (c) We have analyzed the progression of this
myopathy using appropriate markers to assess the chro-
nology of skeletal muscle development.
Material and Methods
Patients
Fifteen newborn infants with genetically characterized
severe myotubular myopathy were enrolled. Patients 8
and 9 are brothers (Table 1). Eight of the 15 XLMTM
patients are described for the first time and for seven of
the 15 patients the molecular defects have been reported
previously (Table 2) (Laporte et al. 1997; Buj-Bello et al.
1999; Biancalana et al. 2003). Prenatal diagnosis was not
made for any patient. At birth, the gestational age of
newborns ranged from 31 to 42 weeks of gestation. Six
boys (Patients 1–6) were born prematurely, between 31
and 36 weeks of gestation, and 9 boys (Patients 7–15)
were born at full term, from 38 to 42 weeks of
gestation (Table 1). Muscle biopsies from vastus lateralis
(n = 4) and deltoid (n = 3) muscles of seven individu-
als with no neuromuscular disorder were used as con-
trols. The “adjusted-age” at muscle biopsy ranged from
37 weeks of gestation to 3 months of age.
Morphological studies
For all 15 patients, an open muscle biopsy was performed
within the first few weeks of life; the age at the time of
the muscle biopsy ranged from 1 day to 3 months of age.
We standardized, the age of newborns as “adjusted-age”
at muscle biopsy, and arranged the patients in chronolog-
ical order according to the corrected-age (Table 1). The
period analyzed after adjusting the age of the babies
corresponds, chronologically, from 34 weeks of gestation
(Patient 1) to 3 months and 7 days of life (Patient 15);
this allowed us to study a specific period of early life in
human patients. Eight muscle biopsies were taken from
the vastus lateralis and seven biopsies were taken from
the deltoid. Muscle biopsies were obtained after informed
consent by their parents, and all specimens were analyzed
in our research laboratory in Paris.
Histochemical analyses were performed as previously
described (Bevilacqua et al. 2009). The morphometric
analysis was performed separately by three different inves-
tigators. A mean of 500 muscle fibers (range 200–731)
were analyzed for each specimen; four consecutive, nonov-
erlapping fields were counted.
Immunohistochemistry
Frozen muscle samples from seven of the 15 patients were
available for immunohistochemistry (Table 1). The imm-
unoperoxidase techniques were performed as previously
described (Bevilacqua et al. 2009). We quantified the ratio
of satellite cells labeled for Pax7 to the total number of
myonuclei by confocal microscopy. These studies were per-
formed using antibodies directed against Pax7 (mouse
monoclonal IgG1 SC-81648, 1/20, Santa Cruz biotechnol-
ogy, Santa Cruz, CA), Antilaminin (Affinity Isolated Anti-
gen Specific Antibody L9393, 1/50, SIGMA, St. Louis, MO),
and mouse Fab (ChromPure Mouse IgG 015-000-007, 1/50,
Jackson, Baltimore, MD). 40,6-diamidino-2-phenylindole,
dihydrocloride (DAPI) (1/250) stained the DNA.
Electron microscopy
Electron microscopy studies were performed on the 13
biopsies. The total number of satellite cells was counted
on 30 ultra-thin sections and nonoverlapping fields of
muscle specimens for 11 of the patients (Patients 3 to 13,
Table 1) by two different investigators.
Molecular studies
All of the parents gave informed consent for the genetic
analysis. Genomic DNA was extracted from blood sam-
ples by standard methods. For patients 5 and 8 the muta-
ª 2013 The Authors. Brain and Behavior published by Wiley Periodicals, Inc. 477
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tions were detected in the mother’s and the affected
brother’s DNA, respectively. DNAs were studied by direct
sequencing of exons and intron–exon boundaries of the
MTM1 gene as previously described (Buj-Bello et al.
1999). For patients 5 and 11, a deletion was detected and
confirmed by MLPA analysis (kit P309, MRC-Holland,
Amsterdam, the Netherlands) (Table 2). For patient 1,
proteins were extracted from the muscle sample and Wes-
tern blot studies were performed with R2630 and R2827
antibodies as previously described (Tosch et al. 2010). No
sample was available for RNA studies, precluding the
detection of any other intronic mutations.
Statistical analyses
A two-way analysis of variance (ANOVA) was performed
to identify possible effects of population (XLMTM
patients vs. controls) and of muscle (deltoid vs. vastus
lateralis) on muscle fiber size, and % of satellite cells, type
I fibers and central nuclei. The meta-distributions of
muscle fiber size in each population were compared using
the Kolmogorov–Smirnov test. The level of significance
was set at 0.05.
Results
Clinical data
The main symptoms during the pregnancy were reduced
fetal movements, polyhydramnios, and oligohydramnios
(Table 1). Common associated signs were severe hypoto-
nia at birth and respiratory failure requiring assisted
ventilation. Facial weakness and swallowing difficulties
were seen in most patients. Arthrogryposis was found in
only one patient. The progression of the disease was
often serious, 11 of them died before 5 months of age,
three patients were still alive at 2 years and 9 months
(Patient 3), at 7 years (Patient 10), and 9 months of age
(Patient 11). Patient 14 had a relatively good evolution.
Chronology of the appearance of
morphological features in MTM1 patients
A similar morphological pattern was observed in all
muscle biopsies throughout the whole period analyzed,
characterized by the presence of numerous hypotrophic
fibers with central nuclei, compared to controls where the
mean percentage of fibers with central nuclei was <1%
(P < 0.0001) (Fig. 1, haematoxylin-eosin [HE]). With the
oxidative staining, the fibers show a dark central region,
regularly surrounded by a paler peripheral halo (Fig. 1,
NADH-tetrazolium reductase [NADH-TR]). These small
fibers belong to both type 1 and 2 (Fig. 2, ATPase). The
mean percentage of fibers with central nuclei was 56.2%
in vastus lateralis (range 31–84%) and 44.0% in deltoid
(range 27–70%). In the scattered large type 1 fibers, cor-
responding to Wohlfart B fibers, centralized nuclei were
never observed.
The diameters of muscle fibers in XLMTM patients
were significantly smaller than in controls for both mus-
cles (P < 0.0001) (Fig. 3). The deltoid tends to present
with less small fiber size compared to the vastus lateralis
(P = 0.078). The percentage of type I fibers was signifi-
cantly higher in the patients compared to the controls
Table 2. Molecular genetics findings.
Patient Adjusted-age MTM1 mutations Exon Notes and references
1 34 w c.638T>C; p.Leu213Pro 8 This paper, missense mutation first described.
Note 1: protein not detected on Western blot analysis.
2 35 w c.1464-1467delACAG; p.Gln489Argfs X12 13 Patient FS30 in Buj-Bello et al. (1999).
3 36 w c.1354-1 G>A 13 This paper.
4 36 w c.141-144delAGAA; p.Glu48Leufs X24 4 This paper.
5 37 w MTM1: c.137-?_(*3357_?)del and
MTMR1: c.(?_-136)_(*2596_?)del
4–15 This paper. Note 2: deletion exons 4–15 of MTM1 and
deletion of MTMR1. Detected in his mother’s DNA.
6 37 w c.1279delA+c.1333-1345del13 12 Patient FN86 in Buj-Bello et al. (1999).
7 39 w c.1260-10A>G; p.FIQ420-421 ins 12 Patient JH64 in Biancalana et al. (2003).
8 39 w c.343-2A>C 6 This paper. Note 3: Detected in his affected brother’s DNA.
9 39 w c.343-2A>C 6 Patient CU15 in Laporte et al. (1997).
10 0 m 7 days c.526C>T; p.Gln176X 7 Patient GF36 in (Biancalana et al. (2003).
11 0 m 15 days c.-10-?_678+?del 2–8 Patient CM73 in Laporte et al. (1997). Note 4:
deletion exons 2–8 of MTM1.
12 0 m 21 days c.205C>T; p.Arg69Cys 4 This paper.
13 1 m 15 days c.1261C>T; p.Arg421 X 12 This paper.
14 2 m c.535C>T; p.Pro179Ser 8 Patient EO38 in Buj-Bello et al. (1999).
15 3 m 7 days c.1395-1397dupAAT; p.lle466dup 13 This paper.
MTM1, myotubular myopathy; w, weeks; m, months.
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(P = 0.002) and the deltoid presented with a significantly
higher type I fiber ratio (P = 0.035). In the deltoid, the
mean percentage of type 1 fibers was 59.2  6.8% in
patients and 44.9  7.2% in controls. In the vastus later-
alis, the mean percentage of type 1 fibers was
51.1  10.0% in patients and 31.0  11.6% in controls.
(A) (B) (C) (D) (E) (F)
(G) (H) (I) (J) (K) (L)
(M) (N) (O) (P) (Q) (R)
Figure 1. Transverse muscle sections of Patients 6 and 15 with severe X-linked myotubular myopathy showing marked variability in fiber size and
the presence of numerous hypotrophic myofibers with centrally placed nuclei (haematoxylin-eosin [HE]; pictures A and G). The central area of
some muscle fibers showed increased oxidative enzyme activity staining; a pale halo in subsarcolemmal regions is also observed (NADH-
tetrazolium reductase [NADH-TR]; pictures B and H). Muscle sections demonstrate fibers with positive expression of either DHPR (Pictures C and I),
RYR1 (Pictures D and J), or desmin (Pictures E and K) with a labeling increased in the central areas of the fibers. The immunolabeling of Vimentin
is observed in some fibers (Pictures F and L). Control muscle sections (Pictures M–R). d, days; w, weeks; m, months; DHPR, dihydropyridine
receptor-a1subunit; RYR, ryanodine receptor type 1.
(A) (B) (C) (D) (E)
(F) (G) (H) (I) (J)
(K) (L) (M) (N) (O)
Figure 2. Transverse muscle sections of Patients 6 and 15 with severe X-linked myotubular myopathy. The areas surrounding central nuclei show
a reduced amount of ATPase activity, in keeping with a lack of myofibrillar components in this region (ATP pH 9.4; Pictures A and F). Muscle
sections treated with antibodies specific for slow (Pictures B and G), fast (Pictures C and H), neonatal/fetal (Pictures D and I), and developmental
(Pictures E and J) myosin heavy chains. Control muscle sections (Pictures K–O). d, days; w, weeks; m, months.
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Electron microscopic examination of the muscle fibers
revealed central nuclei that frequently had prominent
nucleoli and a substantial amount of hypercondensed
chromatin. In muscle biopsies performed in infants born
at term or later, the myofibrils were well structured,
whereas in biopsies performed at early ages, the myofibrils
appeared less compact (Fig. 4). We observed a consistent
proliferation of T-tubules and sarcoreticulum cisternae in
the central areas of these fibers.
Protein analysis by immunohistochemistry
Immunohistochemical analyses of ryanodine receptor type 1
(RyR1) and dihydropyridine receptor-a1subunit (DHPR)
demonstrated a marked labeling of the sarcoplasmic mesh
or network mainly in the central region of the fibers (Fig. 1).
These results are consistent with those observed with histo-
enzymological and ultrastructural studies, demonstrating the
accumulation of endoplasmic reticulum, triads, Golgi appa-
ratus, and mitochondria in the central area of the fibers.
Desmin antibodies labeled the entire cytoplasm and the
staining was abnormally strong in the central region of
muscle fibers. For vimentin, in both deltoid and vastus
lateralis muscles, both positive and negative fibers were
observed throughout the period analyzed (Fig. 1). The
mean percentage of vimentin-expressing fibers was 3.5%
(range 1.1–8.3%) in vastus lateralis and 5.5% (range 2.8–
8.3%) in deltoid. In control patients no fibers were
labeled for vimentin in biopsies performed on infants
born after 36 weeks of pregnancy.
In all XLMTM biopsies, many fibers were labeled
using anti–slow-myosin heavy chain (MHC) antibody,
while in control muscle sections the number of fibers
which expressed slow-MHC was lower (Table 1). The
mean percent of slow-MHC expressing fibers was 63.6%
(rate 53.8–71.6%) in vastus lateralis and 52.5% (rate
43.9–60.0%) in deltoid. With the anti–fast-MHC anti-
body, a number of fibers exhibited variable intensity of
the stain consistent with the presence of some undiffer-
entiated fibers. Labeling with antibody for the fetal-
MHC detected fibers strongly stained, fibers weakly
labeled, and fibers completely negative. Immunostaining
with antibody against the embryonic-MHC was negative
in all patients except for one (Fig. 2). In the control
muscles most fibers were stained for the fast-MHC while
the number of fibers expressing slow-MHC was less than
in XLMTM patients. No antiembryonic-MHC antibody-
positive fibers were detected in control muscles. With
the antineonatal/fetal MHC antibody, positive fibers were
detected in control muscles of youngest newborns; how-
ever, this immunoreactivity was not detected in control
muscles from the older babies (id. 3 months of age).
Caveolin3 immunolabeling was essentially found at the
sarcolemma in all muscle biopsies, but a weak reaction
was also observed in the cytoplasm in most patients but
not in controls. Dysferlin immunoreactivity was normally
present at the sarcolemma in all patients; however, a dif-
fuse labeling was also observed in the cytoplasm in some
patients (Table 1).
Satellite cell study
The number of satellite cells was counted either by confo-
cal or by electron microscopy. Both methods were not
considered different from data obtained in six subjects
(Wilcoxon signed rank test, P = 0.893). The percentage of
satellite cells was significantly lower for patients compared
to controls (P = 0.001) and significantly lower in the
deltoid compared to the quadriceps (P = 0.013). In the
deltoid, the percentage of satellite cells was 7.33  1.9%
in patients and 13.0  1.0% in controls. In the vastus lat-
eralis, the percentage of satellite cells was 11.3  3.6% in
patients and 16.7  3.4% in controls.
Figure 3. Meta-distribution of muscle fiber size observed in X-linked
myotubular myopathy (XLMTM) patients and controls for the deltoid
and the vastus lateralis muscles. The histograms were normalized to
unit area; the amplitude in each bin is thus expressed as a percentage
of occurrences. The graph shows an obvious shift in myofiber size
distribution toward smaller diameters, in both vastus lateralis and
deltoid, in all patients.
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Molecular data
Among the 15 patients from the present cohort, seven
had small or large deletions and point mutations leading
to premature truncation of the protein (Patients
2,4,5,6,10,11,13), five harbored missense or in-frame
insertions or deletions of amino acids (Patients
1,7,12,14,15), and three displayed changes in the canoni-
cal splice sites (Patients 3,8,9). Patient 1 carried a mis-
sense mutation that has never been described; the
pathogenicity was confirmed through a Western blot
analysis showing no detectable level of myotubularin
(Table 2). There was no correlation between the type of
mutation and age of death.
Discussion
We reevaluated the morphological changes in muscle
biopsies in a series of muscle biopsies from infants with
severe myotubular myopathy genetically characterized.
We focused our chronological analysis on the early period
of life (from 34 weeks of adjusted gestational age to
3 months of age). Clinically, during this early period our
patients presented essentially hypotonia, generalized weak-
ness, and respiratory failure requiring assisted ventilation
(Table 1).
Regarding the evolution of the morphological changes,
we would like to stress that a similar morphological pat-
tern was observed throughout the whole period analyzed.
So, we did not observe any period free of morphological
abnormalities in human skeletal muscle as has been
reported in animal models during early postnatal develop-
ment (Buj-Bello et al. 2002; Beggs et al. 2010). The
morphological signs as centralized nuclei are not present
in the published mammalian models at birth, unlike in
patients. Other abnormalities such as T-tubules and triads
misalignment have not been extensively examined before
2 weeks old in mice. Thus, while some hallmarks of
(A) (B) (C)
(D) (E) (F)
(G) (H) (I)
Figure 4. Ultrastructural analysis of muscle biopsies from Patient 4 (A and B), Patient 5 (C), Patient 7 (D and E), Patient 8 (F), Patient 12 (H), and
Patient 13 (G and I). The transverse sections show myonuclei in the center of the fiber often bordered by mitochondria, glycogen, and tubular
structures (Pictures A, C, D, F–I). In sections crossing the muscle fibers between two adjacent nuclei, the central area of the fibers displays a
reduction of myofilaments; the space is occupied by mitochondria, glycogen, and tubular structures (Pictures B, E). Numerous cisterns
corresponding to endoplasmic reticulum, triads, and Golgi complexes are found especially in the central areas of the fibers (Pictures B, E, H).
Longitudinal sections for visualizing the mitochondria and glycogen that aggregate around the poles of the nucleus (E). The satellite cells are
located beneath the basal lamina that surrounds each fiber. The nucleus of the satellite cells usually appears darker (with condensed chromatin)
than the central nucleus in the muscle fibers (Pictures C, F, I).
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CNM are not present, additional studies are required to
assess if other alterations are present in the mammalian
models. In addition, the proportion of myofibers with
central nuclei was high in all muscle biopsies, indepen-
dently of the muscle or of the adjusted-age of the patient
at the time of biopsy; consequently, we demonstrate that
in humans there was no correlation between the number
of myofibers with central nuclei and the age of the new-
borns or the type of muscle biopsied.
In all cases, the type 1 Wolfhart B fibers had a normal
spatial distribution. Of note, these large type 1 fibers,
descending from the first generation of myoblasts which
fuse to form the primary generation muscle fibers (But-
ler-Browne et al. 1990; Barbet et al. 1991), always contain
nuclei in a subsarcolemmal location. This suggests that
the underlying defect is expressed only in muscle fibers
from this second wave of myogenesis.
Immunohistochemical stains on most of the muscle
samples from patients with XLMTM demonstrated a per-
sistence of fetal-specific muscle isoforms or proteins such
as desmin, vimentin, and fetal myosin heavy chain, in
agreement with previous observations (Sarnat 1990; Sous-
si-Yanicostas et al. 1991; Sewry 1998; Romero and Bitoun
2011). However, we also show a consistent increase in the
intensity of labeling with antibodies for DHPRa1s, a
protein/channel of the T-tubule, and RYR1, a protein/
channel of the sarcoplasmic reticulum, mainly in the
central areas of the myofibers, consistent with the ultra-
structural findings (Figs. 1, 4).
On ultrastructural analysis, in biopsies performed at
early ages, the myofibrils appeared less compact and their
structure less dense; this difference could also reflect a
delay in muscle maturation. We have observed a consis-
tent proliferation of T-tubules and sarcoreticulum cister-
nae in the central areas of these fibers, which
substantiates the alteration defined by immunohistochem-
istry displaying a marked labeling mainly in the central
areas of the fibers (Figs. 1, 4). This is in agreement with
findings in both animal models and other forms of cen-
tronuclear myopathies, where T-tubule markers have
been found to be altered (Al-Qusairi et al. 2009; Dowling
et al. 2009; Romero and Bitoun 2011; Toussaint et al.
2011). T-tubule disorganization visualized by immunohis-
tochemistry has already been described in X-linked cen-
tronuclear myopathy (XLCNM) which is in agreement
with the abnormal distribution of DHPRa1 and RyR1.
Moreover, we suggest that there is a more general disor-
ganization of the membrane compartments, including the
sarcoplasmic reticulum. Apart from possible functional
defects arising from mispositioning of the T-tubules,
these additional alterations may have a strong relevance
for the pathological mechanism. The additional finding
that caveolin and dysferlin were abnormally located in
the cytosolic compartment suggests that additional mem-
brane compartments are mislocalized around central
nuclei or that transport of these proteins to the sarco-
lemma is altered. Desmin was also accumulated in the
central areas of myofibers, suggesting that an alteration of
the cytoskeleton is linked to the mispositioning of these
diverse membranous compartments. These latter findings
correlate with observations made in the Mtm1-null mice
(Hnia et al. 2011).
The fusion of satellite cells with myofibers is a basic
mechanism promoting fiber growth and hypertrophy
(Relaix et al. 2006; Zammit et al. 2006; Relaix and
Marcelle 2009). As myotubularin has a major role in the
regulation of signaling pathways involved in growth and
differentiation of muscle fibers (Razidlo et al. 2011), it
seemed important to measure the number of satellite cells
observed in the muscle biopsies of XLMTM infants by
both confocal and electron microscopy. Interestingly, the
ratio of satellite cell labeling by Pax7 to the total number
of myonuclei evolves differently according to the muscle
territory during the early period of life. In XLMTM
patients, there were fewer Pax7-labeled satellite cells in
deltoid than in vastus lateralis muscles (Table 1); in both
muscles these percentages were lower than in control
muscle biopsies. Our findings validate earlier studies
using electron microscopy (Tome and Fardeau 1986).
This finding is extremely important as it would suggest
that even at these very early stages there is a defect in
production of satellite cells. Therefore, the small diameter
of the muscle fibers observed in XLMTM patient biopsies
could be at least partially explained by the decreased
number of satellite cells. A recent study also reported a
significant decrease in satellite cells in the Mtm1-null mice
(Lawlor et al. 2012). Our findings are in stark contrast to
those observed in clinical and pathological closely similar
conditions such as congenital myotonic dystrophy in
which the number of satellite cells is markedly increased.
Histological and structural alterations were observed in
all patient biopsies at all ages investigated. This is in con-
trast to what has been reported for the Mtm1-null mice
which although they reproduced the main histological
signs of XLMTM, remain clinically asymptomatic during
the first 3 weeks of life and only later developed a
progressive myopathy (Buj-Bello et al. 2002). Moreover,
Labrador retrievers with mutated myotubularin are
clinically normal at birth and begin to exhibit progressive
generalized muscle weakness and atrophy from 7 weeks of
age (Beggs et al. 2010). This apparent discrepancy may be
due to the fact that muscle maturation is achieved before
birth in humans while late steps of maturation are com-
pleted within the first weeks after birth in mice and dogs.
There was no strong correlation between the type of
mutation and the age of death or the muscle defects
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noted on biopsies. A possible explanation is that missense
and truncating mutations have a similar impact on the
function of the protein. Indeed, previous experiments
showed that most missense mutations are linked to a
large decrease in the protein level, sustaining this hypoth-
esis (Laporte et al. 2001; Tosch et al. 2010).
In conclusion this sequential morphological study in
myotubular myopathy has shown that in humans there is
no period free from morphological abnormalities in the
skeletal muscle which is in contrast to what has been
observed in mammalian models. We have also demon-
strated a more general disorganization of membrane com-
partments as evidenced by the presence of a significant
disorganization of the cytoskeletal network, the consistent
proliferation of T-tubules and the cisternae of the sarco-
plasmic reticulum. These changes cannot be explained
solely by a delayed maturation of the muscle fiber.
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